Ameriprise
AVDL

Ameriprise’s Avadel Pharmaceuticals AVDL Stock Holding History

Ameriprise’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-351,924
Closed -$7.58M – 4059
2025
Q4 		$7.58M Sell
351,924
-48,199
-12% -$936K ﹤0.01% 2134
2025
Q3 		$6.11M Sell
400,123
-3,710
-0.9% -$48.3K ﹤0.01% 2283
2025
Q2 		$3.57M Buy
403,833
+28,592
+8% +$251K ﹤0.01% 2603
2025
Q1 		$2.94M Buy
375,241
+36,321
+11% +$304K ﹤0.01% 2680
2024
Q4 		$3.56M Sell
338,920
-7,550
-2% -$91.7K ﹤0.01% 2603
2024
Q3 		$4.54M Buy
346,470
+45,530
+15% +$694K ﹤0.01% 2441
2024
Q2 		$4.23M Buy
300,940
+9,666
+3% +$158K ﹤0.01% 2432
2024
Q1 		$4.92M Buy
291,274
+2,160
+0.7% +$32.2K ﹤0.01% 2384
2023
Q4 		$4.08M Buy
289,114
+4,101
+1% +$48.2K ﹤0.01% 2500
2023
Q3 		$2.94M Buy
285,013
+23,334
+9% +$313K ﹤0.01% 2633
2023
Q2 		$4.31M Buy
261,679
+41,084
+19% +$534K ﹤0.01% 2453
2023
Q1 		$2.02M Buy
220,595
+94,421
+75% +$776K ﹤0.01% 2842
2022
Q4 		$903K Buy
126,174
+32,694
+35% +$229K ﹤0.01% 3184
2022
Q3 		$468K Sell
93,480
-18,401
-16% -$101K ﹤0.01% 3417
2022
Q2 		$273K Sell
111,881
-16,968
-13% -$69.7K ﹤0.01% 3599
2022
Q1 		$880K Sell
128,849
-13,402
-9% -$92.1K ﹤0.01% 3269
2021
Q4 		$1.15M Sell
142,251
-263,400
-65% -$2.41M ﹤0.01% 3193
2021
Q3 		$3.98M Buy
405,651
+6,896
+2% +$54.3K ﹤0.01% 2544
2021
Q2 		$2.7M Buy
398,755
+1,042
+0.3% +$8.28K ﹤0.01% 2789
2021
Q1 		$3.57M Buy
397,713
+23,928
+6% +$193K ﹤0.01% 2595
2020
Q4 		$2.5M Sell
373,785
-1,640
-0.4% -$10.3K ﹤0.01% 2679
2020
Q3 		$1.89M Buy
375,425
+31,900
+9% +$232K ﹤0.01% 2697
2020
Q2 		$2.78M Sell
343,525
-92,495
-21% -$815K ﹤0.01% 2434
2020
Q1 		$3.46M Sell
436,020
-44,440
-9% -$341K ﹤0.01% 2157
2019
Q4 		$3.63M Sell
480,460
-284,110
-37% -$1.5M ﹤0.01% 2424
2019
Q3 		$3.18M Buy
764,570
+25,600
+3% +$64.1K ﹤0.01% 2453
2019
Q2 		$2.13M Buy
738,970
+201,869
+38% +$347K ﹤0.01% 2713
2019
Q1 		$773K Buy
537,101
+33,231
+7% +$75.2K ﹤0.01% 3135
2018
Q4 		$1.3M Buy
503,870
+181,285
+56% +$616K ﹤0.01% 2831
2018
Q3 		$1.41M Buy
322,585
+6,271
+2% +$33.9K ﹤0.01% 2948
2018
Q2 		$1.93M Buy
316,314
+76,783
+32% +$539K ﹤0.01% 2747
2018
Q1 		$1.74M Buy
239,531
+27,013
+13% +$238K ﹤0.01% 2738
2017
Q4 		$1.73M Buy
212,518
+8,350
+4% +$78.3K ﹤0.01% 2726
2017
Q3 		$2.14M Buy
204,168
+17,551
+9% +$168K ﹤0.01% 2577
2017
Q2 		$2.06M Sell
186,617
-2,360
-1% -$23.7K ﹤0.01% 2591
2017
Q1 		$1.83M Buy
188,977
+4,902
+3% +$49K ﹤0.01% 2620
2016
Q4 		$1.91M Buy
184,075
+7,718
+4% +$84.8K ﹤0.01% 2646
2016
Q3 		$2.17M Buy
176,357
+11,166
+7% +$146K ﹤0.01% 2531
2016
Q2 		$1.77M Buy
165,191
+18,570
+13% +$198K ﹤0.01% 2585
2016
Q1 		$1.57M Sell
146,621
-9,957
-6% -$98.9K ﹤0.01% 2639
2015
Q4 		$1.91M Sell
156,578
-5,402
-3% -$84.2K ﹤0.01% 2632
2015
Q3 		$2.64M Sell
161,980
-391,817
-71% -$8.63M ﹤0.01% 2461
2015
Q2 		$11.7M Buy
553,797
+101,618
+22% +$1.82M 0.01% 1451
2015
Q1 		$8.13M Buy
+452,179
New +$7.08M ﹤0.01% 1730
2014
Q4 		– Sell
-115
Closed -$2K – 3739
2014
Q3 		$2K Buy
115
+11
+11% +$158 ﹤0.01% 5391
2014
Q2 		$2K Buy
104
+93
+845% +$1.12K ﹤0.01% 5198
2014
Q1 		$0 Sell
11
-10
-48% -$107 ﹤0.01% 5317
2013
Q4 		$0 Hold
21
– – ﹤0.01% 5145
2013
Q3 		$0 Hold
21
– – ﹤0.01% 5602
2013
Q2 		$0 Buy
+21
New +$108 ﹤0.01% 5539

Other funds holding AVDL

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Ameriprise's AVDL Position: Q1 2026 in Review

Ameriprise sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 351,924 shares — an estimated $7.58M sold.

Ameriprise first reported a position in AVDL in Q2 2013 and held it in 50 quarters. The position peaked at $11.7M in Q2 2015. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

  • Ameriprise reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Ameriprise sold 351,924 Avadel Pharmaceuticals shares in Q1 2026, an estimated $7.58M.
  • Ameriprise first reported a position in Avadel Pharmaceuticals in Q2 2013 and held it in 50 quarters.
  • Ameriprise's Avadel Pharmaceuticals position peaked at $11.7M in Q2 2015.
  • 2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.